{"nctId":"NCT02605174","briefTitle":"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine","startDateStruct":{"date":"2016-05"},"conditions":["Migraine With or Without Aura"],"count":3005,"armGroups":[{"label":"Lasmiditan 50 milligram (mg)","type":"EXPERIMENTAL","interventionNames":["Drug: Lasmiditan 50 mg"]},{"label":"Lasmiditan 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lasmiditan 100 mg"]},{"label":"Lasmiditan 200 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lasmiditan 200 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Lasmiditan 50 mg","otherNames":["LY573144"]},{"name":"Lasmiditan 100 mg","otherNames":["LY573144"]},{"name":"Lasmiditan 200 mg","otherNames":["LY573144"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Able and willing to give written informed consent and authorize HIPAA.\n* Participants with migraine with or without aura fulfilling the International Headache Society (IHS) diagnostic criteria 1.1 and 1.2.1 (International Headache Classification (ICHD) 2004).\n* History of disabling migraine for at least 1 year.\n* Migraine Disability Association (MIDAS) score ≥11.\n* Migraine onset before the age of 50 years.\n* History of 3 - 8 migraine attacks per month (\\< 15 headache days per month).\n* Male or female, aged 18 years or above.\n* Females of child-bearing potential must be using or willing to use a highly effective form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD), abstinence or vasectomized partner).\n* Able and willing to complete an electronic diary to record details of the migraine attack treated with study drug.\n\nExclusion Criteria:\n\n* Any medical condition or clinical laboratory test which in the judgment of the Investigator makes the participant unsuitable for the study.\n* Pregnant or breast-feeding women.\n* Women of child-bearing potential not using or not willing to use highly effective contraception.\n* Known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets, or any sensitivity to lasmiditan.\n* History or evidence of hemorrhagic stroke, epilepsy or any other condition placing the participant at increased risk of seizures.\n* History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo (BPPV), Meniere's disease, vestibular migraine, and other vestibular disorders.\n* History of diabetes mellitus with complications (diabetic retinopathy, nephropathy or neuropathy).\n* History within the previous three years or current evidence of abuse of any drug, prescription or illicit, or alcohol.\n* History of orthostatic hypotension with syncope.\n* Significant renal or hepatic impairment.\n* Participant is at imminent risk of suicide (positive response to question 4 or 5) on the Columbia-Suicide Severity Rating Scale (C-SSRS) or had a suicide attempt within six months prior to screening.\n* Previous participation in this clinical trial.\n* Participation in any clinical trial of an experimental drug or device in the previous 30 days.\n* Known Hepatitis B or C or HIV infection.\n* History, within past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (e.g. hemicranias continua, medication overuse headache) where headache frequency is ≥15 headache days per month.\n* Use of more than 3 doses per month of either opiates or barbiturates.\n* Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes within three (3) months prior to Screening/Visit 1.\n* Participants who are employees of the sponsor.\n* Relatives of, or staff directly reporting to, the Investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Headache Pain Free at 2 Hours Post Dose","description":"The percentage of participants defined as mild, moderate, or severe headache pain becoming none.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"31.4","spread":null},{"groupId":"OG002","value":"38.8","spread":null},{"groupId":"OG003","value":"21.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free","description":"The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.8","spread":null},{"groupId":"OG001","value":"44.2","spread":null},{"groupId":"OG002","value":"48.7","spread":null},{"groupId":"OG003","value":"33.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Headache Relief","description":"The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.0","spread":null},{"groupId":"OG001","value":"64.8","spread":null},{"groupId":"OG002","value":"65.0","spread":null},{"groupId":"OG003","value":"47.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Headache Recurrence","description":"The number of participants with headache recurrence (moderate or severe at baseline which became pain-free at 2 hours post dose and worsened again up to 48 hours post dose)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"52","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Use of Rescue Medication","description":"The percentage of participants who used rescue medication.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":null},{"groupId":"OG001","value":"26.4","spread":null},{"groupId":"OG002","value":"18.9","spread":null},{"groupId":"OG003","value":"40.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Use of Rescue Medication","description":"The percentage of participants who used rescue medication.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"6.3","spread":null},{"groupId":"OG002","value":"7.4","spread":null},{"groupId":"OG003","value":"8.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Use of Rescue Medication","description":"The percentage of participants who used rescue medication.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Nausea Free","description":"The percentage of participant without nausea.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.7","spread":null},{"groupId":"OG001","value":"71.8","spread":null},{"groupId":"OG002","value":"70.4","spread":null},{"groupId":"OG003","value":"70.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Phonophobia Free","description":"The percentage of participants without phonophobia.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.2","spread":null},{"groupId":"OG001","value":"64.8","spread":null},{"groupId":"OG002","value":"65.3","spread":null},{"groupId":"OG003","value":"53.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Photophobia Free","description":"The percentage of participants without photophobia.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":null},{"groupId":"OG001","value":"56.4","spread":null},{"groupId":"OG002","value":"58.2","spread":null},{"groupId":"OG003","value":"43.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Resource Utilization","description":"Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"2.8","spread":null},{"groupId":"OG003","value":"2.4","spread":null},{"groupId":"OG004","value":"3.2","spread":null},{"groupId":"OG005","value":"3.3","spread":null},{"groupId":"OG006","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0.5","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0.9","spread":null},{"groupId":"OG005","value":"0.5","spread":null},{"groupId":"OG006","value":"0.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Treatment Emergent Events","description":"Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null},{"groupId":"OG001","value":"230","spread":null},{"groupId":"OG002","value":"253","spread":null},{"groupId":"OG003","value":"75","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":429},"commonTop":["Dizziness","Somnolence","Paraesthesia","Fatigue","Nausea"]}}}